Erste Asset Management Gmb H Atara Biotherapeutics, Inc. Transaction History

Erste Asset Management Gmb H

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 26, 2024	SELL	$1.41 - $2.31 $31,020 - $50,820	-22,000 Closed	0 $0
Q3 2022 Nov 26, 2024	BUY	$2.85 - $8.73 $62,700 - $192,060	22,000 New	22,000 $79.9 Million
Q2 2022 Nov 26, 2024	BUY	$4.69 - $9.84 $103,180 - $216,480	22,000 New	22,000 $167 Million
Q4 2021 Nov 22, 2024	BUY	$14.7 - $19.89 $323,400 - $437,580	22,000 New	22,000 $375 Million
Q4 2020 Nov 22, 2024	BUY	$12.67 - $26.23 $278,740 - $577,060	22,000 New	22,000 $449 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.34B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.